主持制定了我国首个《胰腺癌综合诊治中国专家共识》和中国临床肿瘤学会首个《CSCO胰腺癌诊疗指南》，主持包括自然基金重大研究计划在内的 6 项国家自然基金项目、2项重大新药创制项目和10 多项各类基金项目；现为《Journal of  Pancreatology》 《肿瘤》副主编、《Cancer  Research》《JHO》《临床肿瘤学》等杂志编委，发表SCI论文100余篇，他引1000余次 。 1. Cui J#, Qin S#*, Zhou Y, Zhang S, Sun X, Zhang M, Cui J, Fang W, Gu K, Li Z, Wang J, Chen X, Yao J, Zhou J, Wang G, Bai Y, Xiao J, Qiu W, Wang B, Xia T, Wang C, Kong L, Yin J, Zhang T, Shen X, Fu D, Gao C, Wang H, Wang Q, Wang L*. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduct Target Ther. 2024;9(1):248.（末尾通讯作者2024 IF=40.8） 2. Xu H#*, Xue S#, Sun Y#, Ma J, Li S, Wang Y, Mao T, Ge W, Yue M, Shentu D, Lu W, Wang Y, Hu J, Cui J, Zhang X, Cai L*, Wang Y*, Wang L*. CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment. J Immunother Cancer. 2025;13(1):010029. （末尾通讯作者2025 IF=10.3） 3. Zhang X#, Mao T#, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Li S, Yue M, Ma J, Yao J, Wang Y, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L*, Wang L*. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Cancer Commun (Lond). 2022;42(1):70-74.（末尾通讯作者2022 IF=20.1） 4. Wang Y#, Liang Y#, Xu H#, Zhang X, Mao T, Cui J, Yao J, Wang Y, Jiao F, Xiao X, Hu J, Xia Q, Zhang X, Wang X, Sun Y, Fu D, Shen L, Xu X*, Xue J*, Wang L*. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov. 2021;7(1):36.（末尾通讯作者2021 IF=13） 5. Zhang X#, Mao T#, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Ge W, Li S, Yue M, Ma J, Yao J, Wang Y, Wang Y, Shentu D, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L*, Wang L*. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine. 2022;77:103897. （末尾通讯作者2022 IF=9.7） 6. Li S, Yue M, Xu H, Zhang X, Mao T, Quan M, Ma J, Wang Y, Ge W, Wang Y, Xue S, Shentu D, Cui J*, Wang L*. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Cancer Lett. 2023;564:216206.（末尾通讯作者2023 IF=9.1） 7. Ge W#, Yue M#, Lin R#, Zhou T, Xu H, Wang Y*, Mao T, Li S, Wu X, Zhang X, Wang Y, Ma J, Wang Y, Xue S, Shentu D, Cui J*, Wang L*. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Cancer Lett. 2023;558:216095.（末尾通讯作者2023 IF=9.1） 8. Ge W#, Wang Y#, Quan M#*, Mao T, Bischof EY, Xu H, Zhang X, Li S, Yue M, Ma J, Yang H, Wang L, Yu Z*, Wang L*, Cui J*. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Mol Cancer. 2024;23(1):48. （共同通讯作者2024 IF=27.7） 9. Wang S#, Xiong Y, Luo Y, Shen Y, Zhang F, Lan H, Pang Y, Wang X, Li X, Zheng X, Lu X, Liu X, Cheng Y, Wu T, Dong Y, Lu Y, Cui J, Jia X, Yang S, Wang L*, Wang Y*. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. EMBO Mol Med. 2024 May;16(5):1115-1142.（共同通讯作者2024 IF=9） 10. Xia Q#, Jia J#, Hu C#, Lu J, Li J, Xu H, Fang J, Feng D, Wang L*, Chen Y*. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene. 2022 Feb;41(6):865-877.（共同通讯作者2022 IF=6.9）